The 8 most recent market catalysts affecting $BIVI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 95
BioVie Announces Phase 2 ADDRESS-LC Trial Results Of Bezisterim In Long COVID
BioVie has announced positive topline results from its Phase 2 ADDRESS-LC trial for bezisterim, an investigational drug for Long COVID. The filing highlights statistically signific…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 85
BioVie Says Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID Did Not Achieve Statistical Significance On Any Endpoint In Overall Population, With Significant Results Only In Pre-Specified Subgroups; To Discuss Topline Results On September 15 Call
This headline represents a major negative catalyst for BioVie. The failure of bezisterim to achieve statistical significance in its Phase 2 Long COVID trial's overall population is…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
BioVie shares are trading higher after the company announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
The completion of the last on-treatment visit for BioVie's Phase 2 trial is a significant de-risking event for the company. It signals that the trial has progressed as planned and …
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
BioVie Says Last On-Treatment Visit Completed In Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID; Expects Topline Results Before End Of September 2026
The completion of the last on-treatment visit in a Phase 2 trial is a critical milestone, indicating that the data collection phase is complete and analysis is underway. The expect…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 95
BioVie Q4 EPS $(0.70) Up From $(1.42) YoY
BioVie's Q4 earnings report shows a substantial reduction in per-share losses, moving from $(1.42) to $(0.70) year-over-year. This 50.7% improvement suggests better financial manag…
Aug 12, 2026
Market Technicals
Bullish
Impact 55
12 Health Care Stocks Moving In Wednesday's Intraday Session
This filing is a snapshot of intraday trading activity in the healthcare sector, specifically highlighting companies with notable price changes. The primary drivers for some of the…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 95
BioVie Says Phase 2 SUNRISE-PD Trial Of Bezisterim In Early Parkinson's Disease Met Prespecified Endpoints, Showing Statistically Significant Motor And Non-Motor Improvements vs. Placebo
The successful Phase 2 trial for BioVie's bezisterim in early Parkinson's disease is a significant corporate catalyst. Meeting prespecified endpoints with statistically significant…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.